Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Modeling in Therapy

Modeling in Therapy

Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...

Hallucinogens and Psychedelics

Hallucinogens and Psychedelics

Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...

Community Based Intervention

Community Based Intervention

Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...

Psychodynamic Therapy

Psychodynamic Therapy

Psychodynamic therapies emphasize the exploration of unconscious processes and early childhood experiences as fundamental contributors to psychological difficulties. These therapies, deeply rooted in Freud's psychoanalytic theory, aim to uncover and resolve unconscious conflicts, granting individuals insights that promote emotional and behavioral healing. Contemporary psychodynamic approaches have evolved, integrating a broader range of influences and methodologies while still valuing the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.

Journal of psychopharmacology (Oxford, England)·2025

Same author

On Minimizing Risk and Harm in the Use of Psychedelics.

Psychiatric research and clinical practice·2025

Same author

Relationality and Ethics in MDMA-Assisted Therapy.

The American journal of bioethics : AJOB·2025

Same author

Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.

Current topics in behavioral neurosciences·2024

Same author

The Hopkins-Oxford Psychedelics Ethics (HOPE) Working Group Consensus Statement.

The American journal of bioethics : AJOB·2024

Same author

Call for evidence-based psychedelic integration.

Experimental and clinical psychopharmacology·2023

Search research articles

Related Experiment Video

Updated: Nov 10, 2025

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

Published on: January 5, 2018

Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.

Ingmar Gorman^1,2,3,4, Elizabeth M Nielson^1,2,3, Aja Molinar⁵

¹MAPS Public Benefit Corp, Santa Cruz, CA, United States.

Frontiers in Psychology

|April 2, 2021

Summary

Psychedelic Harm Reduction and Integration (PHRI) offers a compassionate clinical approach for patients using psychedelics. This model supports mental health providers in understanding and addressing the unique needs of psychedelic users, shifting focus from abstinence to acceptance.

Keywords:

MDMA PHRI harm reduction integration preparation psilocybin psychedelics psychotherapy

More Related Videos

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Related Experiment Videos

Last Updated: Nov 10, 2025

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

Published on: January 5, 2018

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

Clinical Psychology
Psychiatry
Addiction Medicine

Background:

Psychedelic use is increasing, with growing academic and media interest.
Recent policy changes, including law enforcement deprioritization and compassionate use approvals, highlight the timeliness of psychedelic research.
Mental health providers need to understand the diverse motivations and experiences of psychedelic users.

Purpose of the Study:

Introduce the Psychedelic Harm Reduction and Integration (PHRI) model.
Provide a framework for clinicians working with patients using or considering psychedelics.
Shift clinical perspectives towards acceptance and destigmatization of psychedelic use.

Main Methods:

PHRI integrates harm reduction psychotherapy and psychedelic-assisted psychotherapy principles.
The approach is applicable in both brief and ongoing psychotherapy settings.
Focuses on assessment, preparation, and managing challenging psychedelic experiences.

Main Results:

PHRI offers a transtheoretical and transdiagnostic clinical framework.
It moves beyond traditional addiction treatment paradigms focused on abstinence.
Emphasizes compassionate, destigmatizing acceptance of patient choices regarding psychedelic use.

Conclusions:

PHRI is a timely and relevant clinical model for addressing psychedelic use.
It equips mental health professionals to support a growing patient population.
The model promotes a more accepting and less judgmental approach to psychedelic experiences.